Diseases We Target

We focus on areas of substantial unmet need

diseases we target

Committed to helping Fight Disease

Reata’s lead candidates, omaveloxolone and bardoxolone methyl, are being developed for the treatment of a variety of chronic and genetic diseases for which a substantial unmet need exists. Our pipeline of therapeutics is focused in two main pillars: neurology and chronic kidney disease (CKD), with late stage programs in Friedreich's ataxia, Alport syndrome, and autosomal dominant polycystic kidney disease (ADPKD).